Nivolumab-Induced Exocrine Pancreatic Insufficiency

Immunotherapy is increasingly gaining applicability for several malignancies. While the survival of several malignancies has dramatically improved, immune-related adverse events (irAEs) can occur and can cause severe damage to patients. Side effects such as colitis are well known nowadays; however,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Boudewijn Sweep, Sofie Wilgenhof, Sander Anten
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	immune-related adverse events pancreatic insufficiency nivolumab immunotherapy melanoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e73e450a16834d5bb97a565bf684fb34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e73e450a16834d5bb97a565bf684fb34
record_format	dspace
spelling	oai:doaj.org-article:e73e450a16834d5bb97a565bf684fb342021-12-02T12:40:23ZNivolumab-Induced Exocrine Pancreatic Insufficiency1662-657510.1159/000519588https://doaj.org/article/e73e450a16834d5bb97a565bf684fb342021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519588https://doaj.org/toc/1662-6575Immunotherapy is increasingly gaining applicability for several malignancies. While the survival of several malignancies has dramatically improved, immune-related adverse events (irAEs) can occur and can cause severe damage to patients. Side effects such as colitis are well known nowadays; however, with increased use of immunotherapy, less common side effects should also be addressed. In this article, 2 patients that received nivolumab developed exocrine dysfunction of the pancreas. Endocrine dysfunction has been well known, but exocrine dysfunction is less often described. It is important to be aware of this side effect because it is possibly underdiagnosed. Symptoms often mimic symptoms of malignancy, chemotherapy side effects, or immune-related colitis. Although the exact mechanism is yet to be elaborated, dormant CD8+ T cells are likely to be involved. No known therapy is yet been proven to be effective. More knowledge and research about irAEs will lead to possible therapies that will be effective. Currently, high-dose prednisone is recommended based on expert opinion.Boudewijn SweepSofie WilgenhofSander AntenKarger Publishersarticleimmune-related adverse eventspancreatic insufficiencynivolumabimmunotherapymelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1627-1631 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune-related adverse events pancreatic insufficiency nivolumab immunotherapy melanoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune-related adverse events pancreatic insufficiency nivolumab immunotherapy melanoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Boudewijn Sweep Sofie Wilgenhof Sander Anten Nivolumab-Induced Exocrine Pancreatic Insufficiency
description	Immunotherapy is increasingly gaining applicability for several malignancies. While the survival of several malignancies has dramatically improved, immune-related adverse events (irAEs) can occur and can cause severe damage to patients. Side effects such as colitis are well known nowadays; however, with increased use of immunotherapy, less common side effects should also be addressed. In this article, 2 patients that received nivolumab developed exocrine dysfunction of the pancreas. Endocrine dysfunction has been well known, but exocrine dysfunction is less often described. It is important to be aware of this side effect because it is possibly underdiagnosed. Symptoms often mimic symptoms of malignancy, chemotherapy side effects, or immune-related colitis. Although the exact mechanism is yet to be elaborated, dormant CD8+ T cells are likely to be involved. No known therapy is yet been proven to be effective. More knowledge and research about irAEs will lead to possible therapies that will be effective. Currently, high-dose prednisone is recommended based on expert opinion.
format	article
author	Boudewijn Sweep Sofie Wilgenhof Sander Anten
author_facet	Boudewijn Sweep Sofie Wilgenhof Sander Anten
author_sort	Boudewijn Sweep
title	Nivolumab-Induced Exocrine Pancreatic Insufficiency
title_short	Nivolumab-Induced Exocrine Pancreatic Insufficiency
title_full	Nivolumab-Induced Exocrine Pancreatic Insufficiency
title_fullStr	Nivolumab-Induced Exocrine Pancreatic Insufficiency
title_full_unstemmed	Nivolumab-Induced Exocrine Pancreatic Insufficiency
title_sort	nivolumab-induced exocrine pancreatic insufficiency
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/e73e450a16834d5bb97a565bf684fb34
work_keys_str_mv	AT boudewijnsweep nivolumabinducedexocrinepancreaticinsufficiency AT sofiewilgenhof nivolumabinducedexocrinepancreaticinsufficiency AT sanderanten nivolumabinducedexocrinepancreaticinsufficiency
_version_	1718393772957499392

Nivolumab-Induced Exocrine Pancreatic Insufficiency

Ejemplares similares